CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
9.64
-0.44 (-4.37%)
At close: Nov 20, 2024, 4:00 PM
9.77
+0.13 (1.35%)
After-hours: Nov 20, 2024, 5:38 PM EST
CervoMed Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CervoMed stock have an average target of 53.67, with a low estimate of 34 and a high estimate of 70. The average target predicts an increase of 456.74% from the current stock price of 9.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CervoMed stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 5 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 4 | 4 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $34 | Strong Buy | Initiates | $34 | +252.70% | Nov 18, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $55 | Strong Buy | Maintains | $55 | +470.54% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +470.54% | Sep 18, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $35 | Buy | Initiates | $35 | +263.07% | Jul 26, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +574.27% | Jul 25, 2024 |
Financial Forecast
Revenue This Year
11.05M
from 7.14M
Increased by 54.67%
Revenue Next Year
4.08M
from 11.05M
Decreased by -63.08%
EPS This Year
-1.58
from -0.82
EPS Next Year
-2.59
from -1.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 13.0M | 7.1M | n/a | ||
| Avg | 11.1M | 4.1M | n/a | ||
| Low | 7.9M | 1.4M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 82.2% | -35.4% | - | ||
| Avg | 54.7% | -63.1% | - | ||
| Low | 11.1% | -87.6% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.38 | -1.32 | -1.33 | ||
| Avg | -1.58 | -2.59 | -3.47 | ||
| Low | -1.70 | -3.39 | -5.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.